Disruption of Survivin in K562 cells elevates telomerase activity and protects cells against apoptosis induced by the Bcr-abl kinase inhibitor STI571.
The Bcr-abl kinase inhibitor STI571 produces clinical responses in most patients with Chronic Myeloid Leukemia (CML); however, development of resistance limits utility. One strategy to overcome STI571 resistance is to decrease the level/activity of Bcr-abl. We reported that disruption of the anti-apoptotic protein Survivin promoted STI571-induced apoptosis in Bcr-abl(+) K562 cells, through caspase-dependent Bcr-abl degradation. To investigate the utility of Survivin disruption in drug-resistant CML cells, we generated STI571-resistant K562 cells by long-term culture with STI571. In contrast to parental cells, where Survivin disruption enhances STI571-induced apoptosis, Survivin disruption in STI571-resistant cells failed to promote STI571-induced apoptosis; rather it protected cells from STI571 and other apoptosis-inducing compounds. Even though Survivin levels were similar in parental and STI571-resistant K562 cells, Survivin disruption in STI571-resistant cells increased telomerase activity, likely due to Bcr-abl/c-abl degradation. Our results indicate that emergence of STI571 resistance in Bcr-abl(+) K562 cells results from induction of additional pathways that circumvent STI571-responsiveness.
Wang
Zhanxiang
Z
Department of Microbiology & Immunology, and the Walther Oncology Center, Indiana University School of Medicine, Indianapolis, IN 46202.
Pelus
Louis M
LM